Cargando…

Successful Use of Recombinant Activated Factor VII to Reverse Ticagrelor-Induced Bleeding Risk: A Case Report

Management of ticagrelor-associated bleeding is challenging, especially in neurosurgery. Platelet transfusion is inefficient and no antidote is currently available. We report here the first case of recombinant activated factor VII (rFVIIa) use to bypass ticagrelor-induced platelet inhibition. A woma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Godier, Anne, Dupont, Mélanie, Desilles, Jean-Philippe, Le Guerinel, Caroline, Taylor, Guillaume, Perrin, Mathilde, Martin, Anne-Céline, Gaussem, Pascale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524896/ https://www.ncbi.nlm.nih.gov/pubmed/31249959 http://dx.doi.org/10.1055/s-0038-1672211

Ejemplares similares

Comparative In Vitro Study of Various α(2)-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal
por: Porta Bonete, Guillaume, et al.
Publicado: (2020)

Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
por: Jourdi, Georges, et al.
Publicado: (2022)

Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
por: Jourdi, Georges, et al.
Publicado: (2022)

Activated recombinant factor VII in management of bleeding in patients with thrombocytopenia
por: Shulutko, E, et al.
Publicado: (2006)

Recombinant activated factor VII for uncontrolled bleeding postcardiac surgery
por: Habib, Aly Makram, et al.
Publicado: (2016)

Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleeding
por: Klitgaard, Thomas, et al.
Publicado: (2006)

Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients
por: AlGahtani, Farjah H., et al.
Publicado: (2010)

Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
por: Johansson, Pär I, et al.
Publicado: (2010)

Recombinant activated factor VII for the treatment of bleeding in abdominal surgery and cardiac surgery
por: Michalska, G, et al.
Publicado: (2009)

Use of recombinant activated factor VII for bleeding following resection of mediastinal angiosarcoma
por: Arora, D, et al.
Publicado: (2011)

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding
por: Chang, Zhi-gang, et al.
Publicado: (2020)

Management of Bleeding Events Associated with Antiplatelet Therapy: Evidence, Uncertainties and Pitfalls
por: Godier, Anne, et al.
Publicado: (2020)

Recombinant-activated factor VII in patients with uncontrolled bleeding: A retrospective observational analysis
por: Abuhasna, Said D., et al.
Publicado: (2012)

Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding
por: Habib, Aly Makram
Publicado: (2016)

Tranexamic acid: less bleeding and less thrombosis?
por: Godier, Anne, et al.
Publicado: (2012)

Successful Control of Massive Bleeding in a Child with Burkitt's Lymphoma via a Biosimilar Recombinant Activated Factor VII (AryoSeven™)
por: Goudarzi Pour, Kourosh, et al.
Publicado: (2016)

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery
por: Barua, Anupama, et al.
Publicado: (2011)

Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation
por: Hollis, Allison L., et al.
Publicado: (2016)

Successful use of N-acetyl cysteine and activated recombinant factor VII in fulminant hepatic failure and massive bleeding secondary to dengue hemorrhagic fever
por: Manoj, Edirisooriya Maddumage, et al.
Publicado: (2014)

Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
por: Heslet, Lars, et al.
Publicado: (2006)

Successful use of recombinant activated factor VII (eptacog alfa, Novoseven®) in a refractory bleeding during pediatric cardiac surgery: a case report
por: Ishihara, Mariko, et al.
Publicado: (2015)

Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding – a European perspective
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Experience with a single dose of recombinant activated factor VII for the management of mild-to-moderate bleeds in haemophilia
por: ALMAGRO, D, et al.
Publicado: (2011)

Use of Recombinant Activated Factor VII in Bleeding Lung Transplant Patients Undergoing Perioperative ECMO Therapy †
por: Laxar, Daniel, et al.
Publicado: (2023)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Aspirin/clopidogrel/ticagrelor: Diffuse ooze and bleeding: 2 case reports
Publicado: (2021)

Mutations of TFPI-binding exosites on factor VII cause bleeding phenotypes in factor VII deficiency
por: Seanoon, Karnsasin, et al.
Publicado: (2022)

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients
por: Ng, Heng Joo, et al.
Publicado: (2006)

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?
por: Altman, Raul, et al.
Publicado: (2010)

Factor VII for intractable bleeding after cardiac surgery
por: Kogan, A, et al.
Publicado: (2007)

Successful Hemostasis with Recombinant Activated Factor VII in a Patient with Massive Hepatic Subcapsular Hematoma
por: Lee, Ju-Hee, et al.
Publicado: (2009)

Successful use of recombinant activated factor VII for postoperative associated haemorrhage: a case report
por: Vlachos, Konstantinos, et al.
Publicado: (2008)

Successful hemostasis in refractory alveolar hemorrhage using low-dose recombinant activated factor VII
por: Selickman, John, et al.
Publicado: (2022)

New alternative to antidotes for novel oral anticoagulants and ticagrelor in the case of severe bleeding
por: Honore, Patrick M., et al.
Publicado: (2020)

Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk
por: Tjerkaski, Jonathan, et al.
Publicado: (2023)

Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19?
por: Omarjee, Loukman, et al.
Publicado: (2020)

Age‐Dependent Effect of Ticagrelor Monotherapy Versus Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events: A Post Hoc Analysis of the TICO Randomized Trial
por: Kim, Byung Gyu, et al.
Publicado: (2021)

Activated factor VII in excessive bleeding during ECMO run
por: Kabbani, Mohamed Salim
Publicado: (2017)

Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann’s thrombasthenia
por: Poon, Man-Chiu
Publicado: (2007)

Ineffective off-label use of recombinant activated factor VII in a case of bone-marrow transplantation-related gastrointestinal bleeding
por: Eller, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_foh7ja4o45ombbg256otjp3fel